MIM
STLN

MetLife Investment Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

MetLife Investment Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85.3K Sell
27,790
-12,665
-31% -$38.8K ﹤0.01% 2603
2025
Q4 		$144K Buy
40,455
+18,819
+87% +$69.8K ﹤0.01% 2437
2025
Q3 		$75.5K Sell
21,636
-18,309
-46% -$62.7K ﹤0.01% 2746
2025
Q2 		$81.9K Buy
+39,945
New +$99.9K ﹤0.01% 2639

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MetLife Investment Management's STLN Position: Q1 2026 in Review

MetLife Investment Management reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 31% in Q1 2026, selling an estimated $38.8K and leaving 27,790 shares worth $85.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2603.

MetLife Investment Management first reported a position in STLN in Q2 2025 and has held it in 4 quarters since. The position peaked at $144K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • MetLife Investment Management held 27,790 shares of Starling Oncology Institute, Inc. Common Stock worth $85.3K as of Q1 2026.
  • MetLife Investment Management sold 12,665 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $38.8K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2603 holding.
  • MetLife Investment Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2025 and has held it in 4 quarters since.
  • MetLife Investment Management's Starling Oncology Institute, Inc. Common Stock position peaked at $144K in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.